A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
- PMID: 24894197
- PMCID: PMC4154984
- DOI: 10.1158/1940-6207.CAPR-14-0075
A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Abstract
NKX3.1 is an androgen-regulated prostate tumor suppressor protein. We previously found that antioxidant administration (N-acetylcysteine) in the Nkx3.1 knockout mouse model promoted prostate epithelial proliferation, suggesting that NKX3.1 activity modifies the effect of antioxidant administration on prostate carcinogenesis. Interestingly, administration of the antioxidant vitamin E significantly increased prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), suggesting that our animal experiments may be relevant to humans. To determine whether NKX3.1 played a role in increased human prostate cancer risk associated with antioxidant administration in SELECT, we investigated the joint risk of antioxidant administration and NKX3.1 genotypes previously found to be associated with decreased NKX3.1 mRNA expression (rs11781886) or DNA-binding activity in vitro (rs2228013) in the SELECT biomarker case-cohort substudy (1,866 cases; 3,135 non-cases). Multivariable COX regression models were developed to determine the joint association of NKX3.1 genotypes with administration of vitamin E, selenium, or the combination, compared with placebo. The CC genotype at rs11781886 combined with selenium administration was associated with increased overall prostate cancer risk [HR, 1.676; 95% confidence interval (CI), 1.011-2.777; P = 0.045] and low-grade prostate cancer risk (HR, 1.811; 95% CI, 1.016-3.228; P = 0.0441). Similarly, the rs11781886 minor allele (CC+CT) combined with vitamin E administration was significantly associated with increased prostate cancer risk (HR, 1.450; 95% CI, 1.117-1.882; P = 0.0052). Our results indicate that variation in NKX3.1 expression combined with selenium or vitamin E treatment modifies the risk of prostate cancer. Genetic background may modulate the effects of antioxidant supplementation thought to act as chemoprevention agents.
©2014 American Association for Cancer Research.
Figures
References
-
- Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998;90:440–6. - PubMed
-
- Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608–12. - PubMed
-
- Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol. 2001;166:1311–5. - PubMed
-
- Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Jr, Kristal AR, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) J Natl Cancer Inst. 2005;97:94–102. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR000445/TR/NCATS NIH HHS/United States
- U10 CA037429/CA/NCI NIH HHS/United States
- R01 CA121060/CA/NCI NIH HHS/United States
- UG1 CA189974/CA/NCI NIH HHS/United States
- CA37429/CA/NCI NIH HHS/United States
- R01 CA094858/CA/NCI NIH HHS/United States
- U10 CA32102/CA/NCI NIH HHS/United States
- R01CA121060/CA/NCI NIH HHS/United States
- 2 UL1 TR000445-06/TR/NCATS NIH HHS/United States
- U10 CA032102/CA/NCI NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- R01 CA123484/CA/NCI NIH HHS/United States
- UM1 CA182883/CA/NCI NIH HHS/United States
- R01CA94858/CA/NCI NIH HHS/United States
- UL1 RR024975-01/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical